Table 4.
Association between gene mutations and clinical features in RAIR-DTC patients.
| Characteristics | Mutation | P value | ||
|---|---|---|---|---|
| BRAF V600E negative (n = 18) | BRAF V600E positive (n = 50) | BRAF V600E and TERT mutations (n = 43) | ||
| Age (years) | ||||
| Mean | 44.2 ± 11.2 | 40.6 ± 13.3 | 50.1 ± 13.8 | <.005 |
| <55 | 14 (77.8) | 41 (82) | 26 (60.5) | >.05 |
| ≥55 | 4 (22,2) | 9 (18) | 17 (39.5) | |
| Gender | ||||
| Female | 11 (61.1) | 41 (82) | 31 (72.1) | >.05 |
| Male | 7 (38.9) | 9 (18) | 12 (27.9) | |
| Tumor size (T) | ||||
| T1–2 | 13 (72.2) | 43 (86) | 22 (51.2) | <.001 |
| T3–4 | 2 (11.1) | 5 (10) | 19 (44.2) | |
| Tx | 3 (16.7) | 2 (4) | 2 (4.7) | |
| Lympho note metastasis (N) | ||||
| N0 | 4 (22.2) | 11 (22) | 9 (20.9) | >.05 |
| N1 | 14 (77.8) | 38 (76) | 34 (79.1) | |
| Nx | 0 (0) | 1 (2) | 0 (0) | |
| Distant metastasis (M) | ||||
| M0 | 18 (100) | 50 (100) | 43 (100) | >.05 |
| M1 | 0 (0) | 0 (0) | 0 (0) | |
| RAI total dose (mCi) | ||||
| Medium | 252.5 (218.8–318.8) | 275 (195–350) | 300 (250–450) | >.05 |
| <600 | 16 (88.9) | 47 (94) | 38 (88.4) | >.05 |
| ≥600 | 2 (11.1) | 3 (6) | 5 (11.6) | |
| The number of 131I treatments | ||||
| <3 | 14 (77.8) | 35 (70) | 24 (55.8) | >.05 |
| 3–5 | 3 (16.7) | 13 (26) | 19 (44.2) | |
| ≥6 | 1 (5.6) | 2 (4) | 0 (0) | |
| Suppressed thyroglobulin | ||||
| Medium | 0.12 (0.1–1.2) | 1.26 (0.3–3.1) | 2.46 (0.5–7.9) | <.05 |
| <1 ng/mL | 14 (82.4) | 36 (76.6) | 25 (62.5) | >.05 |
| ≥1 ng/mL | 3 (17.6) | 11 (23.4) | 15 (37.5) | |
| Stimulated thyroglobulin | ||||
| Medium | 7.94 (0.4–36) | 27.79 (4.8–74.1) | 38.2 (14.4–131.5) | <.05 |
| <10 ng/mL | 10 (55.6) | 15 (31.3) | 8 (19.5) | <.05 |
| ≥10 ng/mL | 8 (44.4) | 33 (68.8) | 33 (80.5) | |
| Histopathology | ||||
| C-PTC | 15 (83.3) | 38 (76) | 37 (86) | >.05 |
| Other histological variants | 3 (16.7) | 12 (24) | 6 (14) | |
C-PTC = conventional papillary thyroid carcinoma, RAIR-DTC = radioiodine-refractory differentiated thyroid cancer, TERT = telomerase reverse transcriptase.